A top 3 multinational pharmaceutical and biotechnology company headquartered in the United States. The client aims to bring equity and social justice in access toward quality medicines for individuals. The client focuses to work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time and achieve a healthier world for everyone.
Surge in volume-need to process nonserious cases as high as ~1.2 million in a short period of 6 months
High cost of operations-the cost of end to end processing is around $60 for each case
Lack of automation-existing manual processes require 45 to 50 minutes per case with a majority of the time spent on ICSR identification
We leveraged NEXT Adverse Events Management platform for end to end case processing driven by Artificial Intelligence (AI) and Natural Language Process (NLP) technology. The NEXT Adverse Events Management platform provided auto ingestion of structured docs (CIOMS, MedWatch, Vendor pdf) and unstructured data sources such as free text emails. Complete automation of processes including case prioritization, data entry, causality assessment, and submission in R3 format to Safety DB. Also, we deployed up to 400 highly skilled Pharmacovigilance FTEs in a Managed services model for Quality Check (QC) and Medical Review within a 12-week timeframe.
Our client was able to increase the efficiency of processes up to 60%, while reducing time by up to 50%.
NEXT Adverse Events Management helped client process more than twice the number of cases to help achieve affordable and quality "healthcare for all."